NEW YORK (GenomeWeb News) — Underwriters taking part in Rosetta Genomics’ initial public offering last month bought 562,000 additional shares as part of an over-allotment.
.
The over-allotment makes the total IPO’s net value $26.2 million on 4.3 million shares sold, after the initial sale of 3.75 million shares at $7 a share.
 
Rosetta’s stock was down 2.4 percent at $8.15 in early-afternoon trading today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.